Meet the Board: Optum Rx's David Calabrese Discusses New Role, Pharmacy Deserts, Medication Shortages and More
In the latest episode of the Meet the Board podcast series, Managing Editor, Peter Wehrwein, catches up with Chief Clinical Officer at Optum Rx and EAB member, David Calabrese, about his new role alongside his team's progress in improving quality, patient safety and health equity in healthcare.
In the latest episode of the Meet the Board podcast series, Managing Editor, Peter Wehrwein, catches up with Chief Clinical Officer at Optum Rx and EAB member, David Calabrese, about his new role alongside his team's progress in improving quality, patient safety and health equity in healthcare.
Calabrese
Calabrese highlights efforts to address pharmacy deserts and medication shortages; and the two discuss the challenges and future of retail pharmacies, the impact of cell and gene therapies and the rise of GLP-1 weight loss drugs, noting their cost and regulatory scrutiny.
"(GLP-1s are) probably the hottest area of focus, not just for the PBM and for the payer community, but it has significant implications for the drug supply chain, as well (as) our pharmacies," Calabrese said. "Given the demand, given the price point of these products, the lack of discounting creates a lot of challenges, often pushing our pharmacies into the red and dispensing these therapies.
"It's only going to grow. We know that the demand will continue to increase. I think I've seen projections that we could see two, three-fold increase in demand and utilization of these products over time."
David also emphasized the importance of comprehensive patient support programs.
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Positive Pipeline Updates for Friedreich’s Ataxia
October 24th 2024After experiencing setbacks, PTC reported positive results for vatiquinone, its selective inhibitor of 15-Lipoxygenase (15-LO) enzyme, regulator of the energetic and oxidative stress pathways that are disrupted in Friedreich ataxia
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
